interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Apixaban

Generic competition · all medicines · read 12 November 2026

Is there a generic of Apixaban, and who makes it?

Apixaban appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 2 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Apixaban3 dosage-form groups in the Orange Book
2generic makers listed
  1. Apixaban appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 2 generic makers listed as marketed across them.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 7 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

One to three generic makers listed

Brand listed as marketed: Eliquis. 2 generic makers with 4 generic products listed as marketed; the first generic approval is dated 23 December 2019.

20102015202020252030203502brand 2012Accord Healthcare Inc, first approval 28 July 2020Regcon Holdings Llc, first approval 11 September 2020data datePatent 6967208 listed to expire 21 November 2026Patent 6967208*PED listed to expire 21 May 2027Patent 9326945 listed to expire 24 February 2031Patent 9326945*PED listed to expire 24 August 2031Exclusivity NPP to 17 April 2028Exclusivity PED to 17 October 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Accord Healthcare Inc28 July 20202
Regcon Holdings Llc11 September 20202

Patents and exclusivities still listed

  • 17 April 2028Exclusivity NPP Eliquis
  • 17 October 2028Exclusivity PED Eliquis
  • 21 November 2026Patent 6967208 drug substance
  • 21 May 2027Patent 6967208*PED
  • 24 February 2031Patent 9326945 drug product
  • 24 August 2031Patent 9326945*PED

For Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Eliquis Sprinkle. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 6967208 listed to expire 21 November 2026Patent 6967208*PED listed to expire 21 May 2027Patent 11896586 listed to expire 22 November 2040Patent 11896586*PED listed to expire 22 May 2041Exclusivity NP to 17 April 2028Exclusivity PED to 17 October 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 17 April 2028Exclusivity NP Eliquis Sprinkle
  • 17 October 2028Exclusivity PED Eliquis Sprinkle
  • 21 November 2026Patent 6967208 drug substance
  • 21 May 2027Patent 6967208*PED
  • 22 November 2040Patent 11896586 drug product
  • 22 May 2041Patent 11896586*PED

Tablet, For Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Eliquis. No generic is listed as marketed.

202020252030203501brand 2025data datePatent 6967208 listed to expire 21 November 2026Patent 6967208*PED listed to expire 21 May 2027Patent 9326945 listed to expire 24 February 2031Patent 9326945*PED listed to expire 24 August 2031Exclusivity NS to 17 April 2028Exclusivity PED to 17 October 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 17 April 2028Exclusivity NS Eliquis
  • 17 October 2028Exclusivity PED Eliquis
  • 21 November 2026Patent 6967208 drug substance
  • 21 May 2027Patent 6967208*PED
  • 24 February 2031Patent 9326945 drug product
  • 24 August 2031Patent 9326945*PED

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.